A Novel Peptide Derived From Tissue-Type Plasminogen Activator Potently Inhibits Angiogenesis and Corneal Neovascularization

J Cell Biochem. 2017 May;118(5):1132-1143. doi: 10.1002/jcb.25732. Epub 2017 Jan 10.

Abstract

The recombinant protein TK1-2, which consists of two kringle domains of tissue-type plasminogen activator (t-PA), inhibits angiogenesis and tumor growth. ɪn this study, we examined the anti-angiogenic activities of peptides derived from kringle 2 domain of t-PA to identify the functional core sequence. Seven peptides were constructed from the kringle 2 sequence, based on the structure and characteristics of amino acid residues, and were analyzed for their inhibitory effects on endothelial cells (ECs). Among them, TP-7 (derived from a β-sheet motif) potently inhibited proliferation, tube formation, and migration of ECs in a dose-dependent manner, whereas truncation of 3-9 amino acid residues from either N or C terminus of TP-7 abrogated its inhibitory effects on ECs. TP-7 also potently inhibited angiogenesis in a Matrigel plug assay in vivo. Moreover, TP-7 dose-dependently suppressed corneal neovascularization induced by an acute chemical burn in a rat model. At the molecular level, TP-7 inhibited VEGF- or bFGF-induced phosphorylation of FAK and ERK1/2 and drastically disrupted VEGF- or bFGF-induced formation of stress fibers and focal adhesion complexes. In addition, TP-7 markedly suppressed attachment and spreading of ECs on a collagen type I or fibronectin matrix. Adhesion of ECs to immobilized TP-7 increased dose-dependently, which was disrupted strongly by pretreatment with soluble TP-7 and slightly by an integrin α2β1-blocking antibody. These results suggest that TP-7 is a potent anti-angiogenic peptide in part affecting the integrin α2β1-dependent pathway and that it can be used for treatment of corneal neovascularization by targeting VEGF and non-VEGF pathways. J. Cell. Biochem. 118: 1132-1143, 2017. © 2016 Wiley Periodicals, Inc.

Keywords: ANGIOGENESIS INHIBITOR; CORNEAL NEOVASCULARIZATION; KRINGLE; PEPTIDE; TISSUE-TYPE PLASMINOGEN ACTIVATOR.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Adhesion / drug effects
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Corneal Neovascularization / drug therapy*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Endothelial Cells / cytology*
  • Endothelial Cells / drug effects
  • Fibroblast Growth Factor 2 / pharmacology
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Kringles
  • MAP Kinase Signaling System / drug effects
  • Neovascularization, Pathologic / drug therapy*
  • Peptides / administration & dosage*
  • Peptides / chemical synthesis*
  • Peptides / pharmacology
  • Rats
  • Tissue Plasminogen Activator / chemistry*
  • Vascular Endothelial Growth Factor A / pharmacology

Substances

  • Peptides
  • Vascular Endothelial Growth Factor A
  • Fibroblast Growth Factor 2
  • PLAT protein, human
  • Tissue Plasminogen Activator